{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:32:01Z","timestamp":1788877921524,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"UCLA SPORE in Brain Cancer","award":["NIH\/NCI 1P50CA211015-01A1"],"award-info":[{"award-number":["NIH\/NCI 1P50CA211015-01A1"]}]},{"name":"UCLA SPORE in Brain Cancer","award":["NIH\/NCI 1P50CA211015-01A1"],"award-info":[{"award-number":["NIH\/NCI 1P50CA211015-01A1"]}]},{"name":"American Cancer Society (ACS) Research Scholar Grant","award":["RSG-15-003-01-CCE"],"award-info":[{"award-number":["RSG-15-003-01-CCE"]}]},{"name":"University of California Research Coordinating Committee"},{"name":"UCLA Jonsson Comprehensive Cancer Center Seed Grant"},{"name":"NIH\/NCI","award":["1R21CA223757-01"],"award-info":[{"award-number":["1R21CA223757-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11060-022-04088-3","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T06:02:28Z","timestamp":1658037748000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence, molecular characteristics, and imaging features of \u201cclinically-defined pseudoprogression\u201d in newly diagnosed glioblastoma treated with chemoradiation"],"prefix":"10.1007","volume":"159","clinical-trial-number":[{"clinical-trial-number":"nct00943826","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Akifumi","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schlossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Shabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tatekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Saran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Ellingson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,17]]},"reference":[{"key":"4088_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20:S2-8. https:\/\/doi.org\/10.1188\/16.CJON.S1.2-8","journal-title":"Clin J Oncol Nurs"},{"key":"4088_CR2","volume-title":"Glioblastoma","author":"C Fernandes","year":"2017","unstructured":"Fernandes C, Costa A, Osorio L, Lago RC, Linhares P, Carvalho B, Caeiro C (2017) Current standards of care in glioblastoma therapy. In: De Vleeschouwer S (ed) Glioblastoma. Codon Publications, Brisbane (AU)"},{"key":"4088_CR3","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz","year":"2011","unstructured":"Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978\u20131985. https:\/\/doi.org\/10.3174\/ajnr.A2397","journal-title":"AJNR Am J Neuroradiol"},{"key":"4088_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","volume":"134","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134:495\u2013504. https:\/\/doi.org\/10.1007\/s11060-017-2375-2","journal-title":"J Neurooncol"},{"key":"4088_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26171","author":"SC Thust","year":"2018","unstructured":"Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging. https:\/\/doi.org\/10.1002\/jmri.26171","journal-title":"J Magn Reson Imaging"},{"key":"4088_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453\u2013461. https:\/\/doi.org\/10.1016\/S1470-2045(08)70125-6","journal-title":"Lancet Oncol"},{"key":"4088_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S0140-6736(09)61299-X","volume":"374","author":"C Soussain","year":"2009","unstructured":"Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639\u20131651. https:\/\/doi.org\/10.1016\/S0140-6736(09)61299-X","journal-title":"Lancet"},{"key":"4088_CR8","first-page":"206","volume":"26","author":"W Fiegler","year":"1986","unstructured":"Fiegler W, Langer M, Scheer M, Kazner E (1986) Reversible computed tomographic changes following brain tumor irradiation induced by the \u201cearly-delayed reaction\u201d after radiation. Radiologe 26:206\u2013209","journal-title":"Radiologe"},{"key":"4088_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/02841869009096385","volume":"29","author":"K Watne","year":"1990","unstructured":"Watne K, Hager B, Heier M, Hirschberg H (1990) Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol 29:891\u2013895","journal-title":"Acta Oncol"},{"key":"4088_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/mpo.2950190307","volume":"19","author":"M Griebel","year":"1991","unstructured":"Griebel M, Friedman HS, Halperin EC, Wiener MD, Marks L, Oakes WJ, Hoffman JM, DeLong GR, Schold SC, Hockenberger B et al (1991) Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med Pediatr Oncol 19:182\u2013186","journal-title":"Med Pediatr Oncol"},{"key":"4088_CR11","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1212\/WNL.0b013e31821d74e7","volume":"76","author":"RJ Young","year":"2011","unstructured":"Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918\u20131924. https:\/\/doi.org\/10.1212\/WNL.0b013e31821d74e7","journal-title":"Neurology"},{"key":"4088_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192\u20132197. https:\/\/doi.org\/10.1200\/JCO.2007.14.8163","journal-title":"J Clin Oncol"},{"key":"4088_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","volume":"63","author":"MC de Wit","year":"2004","unstructured":"de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535\u2013537","journal-title":"Neurology"},{"key":"4088_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cncr.23562","volume":"113","author":"W Taal","year":"2008","unstructured":"Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405\u2013410. https:\/\/doi.org\/10.1002\/cncr.23562","journal-title":"Cancer"},{"key":"4088_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1148\/radiol.10091440","volume":"256","author":"R Mangla","year":"2010","unstructured":"Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, Ekholm SE (2010) Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575\u2013584. https:\/\/doi.org\/10.1148\/radiol.10091440","journal-title":"Radiology"},{"key":"4088_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-009-9809-4","volume":"94","author":"ER Gerstner","year":"2009","unstructured":"Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 94:97\u2013101. https:\/\/doi.org\/10.1007\/s11060-009-9809-4","journal-title":"J Neurooncol"},{"key":"4088_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/s0317167100009628","volume":"37","author":"P Sanghera","year":"2010","unstructured":"Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, Lam K, Davey P, Tsao MN (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37:36\u201342. https:\/\/doi.org\/10.1017\/s0317167100009628","journal-title":"Can J Neurol Sci"},{"key":"4088_CR18","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1200\/jco.2008.26.15_suppl.2025","volume":"26","author":"JL Clarke","year":"2008","unstructured":"Clarke JL, Abrey LE, Karimi S, Lassman AB (2008) Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 26:2025","journal-title":"J Clin Oncol"},{"key":"4088_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1148\/radiol.13122024","volume":"269","author":"HH Chu","year":"2013","unstructured":"Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH (2013) Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted Imaging. Radiology 269:831\u2013840. https:\/\/doi.org\/10.1148\/radiol.13122024","journal-title":"Radiology"},{"key":"4088_CR20","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.clon.2007.01.374","volume":"19","author":"S Jefferies","year":"2007","unstructured":"Jefferies S, Burton K, Jones P, Burnet N (2007) Interpretation of early imaging after concurrent radiotherapy and temozolomide in glioblastoma. Clin Oncol (R Coll Radiol) 19:S33","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"4088_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.surneu.2008.09.023","volume":"72","author":"C Chaskis","year":"2009","unstructured":"Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H (2009) Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72:423\u2013428. https:\/\/doi.org\/10.1016\/j.surneu.2008.09.023","journal-title":"Surg Neurol"},{"key":"4088_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00062-017-0584-x","volume":"28","author":"AW Abbasi","year":"2018","unstructured":"Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A (2018) Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 28:401\u2013411. https:\/\/doi.org\/10.1007\/s00062-017-0584-x","journal-title":"Clin Neuroradiol"},{"key":"4088_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"4088_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/radiol.13131305","volume":"271","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200\u2013210. https:\/\/doi.org\/10.1148\/radiol.13131305","journal-title":"Radiology"},{"key":"4088_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/neuonc\/now187","volume":"19","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF (2017) Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol 19:89\u201398. https:\/\/doi.org\/10.1093\/neuonc\/now187","journal-title":"Neuro Oncol"},{"key":"4088_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102882","volume":"32","author":"A Hagiwara","year":"2021","unstructured":"Hagiwara A, Yao J, Raymond C, Cho NS, Everson R, Patel K, Morrow DH, Desousa BR, Mareninov S, Chun S, Nathanson DA, Yong WH, Andrei G, Divakaruni AS, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM (2021) \u201cAerobic glycolytic imaging\u201d of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. Neuroimage Clin 32:102882. https:\/\/doi.org\/10.1016\/j.nicl.2021.102882","journal-title":"Neuroimage Clin"},{"key":"4088_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuroimage.2011.09.076","volume":"59","author":"BM Ellingson","year":"2012","unstructured":"Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 59:908\u2013916. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.09.076","journal-title":"Neuroimage"},{"key":"4088_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11060-021-03730-w","volume":"152","author":"H Tatekawa","year":"2021","unstructured":"Tatekawa H, Uetani H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Bahri S, Pope WB, Salamon N, Ellingson BM (2021) Preferential tumor localization in relation to (18)F-FDOPA uptake for lower-grade gliomas. J Neurooncol 152:573\u2013582. https:\/\/doi.org\/10.1007\/s11060-021-03730-w","journal-title":"J Neurooncol"},{"key":"4088_CR29","unstructured":"Zwanenburg A, Leger S, Valli\u00e8res M, L\u00f6ck S (2016) Image biomarker standardisation initiative. arXiv:1612.07003v11"},{"key":"4088_CR30","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2015.61.5005","volume":"33","author":"T Sandmann","year":"2015","unstructured":"Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C (2015) Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33:2735\u20132744. https:\/\/doi.org\/10.1200\/JCO.2015.61.5005","journal-title":"J Clin Oncol"},{"key":"4088_CR31","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.clon.2007.01.374","volume":"19","author":"S Jefferies","year":"2007","unstructured":"Jefferies S, Burton K, Jones P, Burnet N (2007) Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin Oncol 19:S33","journal-title":"Clin Oncol"},{"key":"4088_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou224","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF (2014) Pros and cons of current brain tumor imaging. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/nou224","journal-title":"Neuro Oncol"},{"key":"4088_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa082","author":"I Alnahhas","year":"2020","unstructured":"Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V (2020) Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaa082","journal-title":"Neuro-Oncol Adv"},{"key":"4088_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010122","author":"C Jungk","year":"2019","unstructured":"Jungk C, Warta R, Mock A, Friauf S, Hug B, Capper D, Abdollahi A, Debus J, Bendszus M, von Deimling A, Unterberg A, Herold-Mende C (2019) Location-dependent patient outcome and recurrence patterns in IDH1-wildtype glioblastoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11010122","journal-title":"Cancers (Basel)"},{"key":"4088_CR35","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1038\/s41598-018-22697-9","volume":"8","author":"S Bette","year":"2018","unstructured":"Bette S, Barz M, Huber T, Straube C, Schmidt-Graf F, Combs SE, Delbridge C, Gerhardt J, Zimmer C, Meyer B, Kirschke JS, Boeckh-Behrens T, Wiestler B, Gempt J (2018) Retrospective analysis of radiological recurrence patterns in glioblastoma, their prognostic value and association to postoperative infarct volume. Sci Rep 8:4561. https:\/\/doi.org\/10.1038\/s41598-018-22697-9","journal-title":"Sci Rep"},{"key":"4088_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2176\/nmc.oa.2013-0226","volume":"54","author":"Y Sonoda","year":"2014","unstructured":"Sonoda Y, Saito R, Kanamori M, Kumabe T, Uenohara H, Tominaga T (2014) The association of subventricular zone involvement at recurrence with survival after repeat surgery in patients with recurrent glioblastoma. Neurol Med Chir (Tokyo) 54:302\u2013309. https:\/\/doi.org\/10.2176\/nmc.oa.2013-0226","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"4088_CR37","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","volume":"28","author":"JK Park","year":"2010","unstructured":"Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM (2010) Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28:3838\u20133843. https:\/\/doi.org\/10.1200\/JCO.2010.30.0582","journal-title":"J Clin Oncol"},{"key":"4088_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11060-017-2685-4","volume":"136","author":"E Audureau","year":"2018","unstructured":"Audureau E, Chivet A, Ursu R, Corns R, Metellus P, Noel G, Zouaoui S, Guyotat J, Le Reste PJ, Faillot T, Litre F, Desse N, Petit A, Emery E, Lechapt-Zalcman E, Peltier J, Duntze J, Dezamis E, Voirin J, Menei P, Caire F, Dam Hieu P, Barat JL, Langlois O, Vignes JR, Fabbro-Peray P, Riondel A, Sorbets E, Zanello M, Roux A, Carpentier A, Bauchet L, Pallud J, Club de Neuro-Oncologie of the Societe Francaise de N (2018) Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. J Neurooncol 136:565\u2013576. https:\/\/doi.org\/10.1007\/s11060-017-2685-4","journal-title":"J Neurooncol"},{"key":"4088_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/jjco\/hyaa162","volume":"51","author":"Y Tabei","year":"2021","unstructured":"Tabei Y, Kobayashi K, Saito K, Shimizu S, Suzuki K, Sasaki N, Shiokawa Y, Nagane M (2021) Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status. Jpn J Clin Oncol 51:45\u201353. https:\/\/doi.org\/10.1093\/jjco\/hyaa162","journal-title":"Jpn J Clin Oncol"},{"key":"4088_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749\u2013762. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141","journal-title":"Nat Rev Clin Oncol"},{"key":"4088_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/RLI.0000000000000666","volume":"55","author":"A Hagiwara","year":"2020","unstructured":"Hagiwara A, Fujita S, Ohno Y, Aoki S (2020) Variability and standardization of quantitative imaging: monoparametric to multiparametric quantification, radiomics, and artificial intelligence. Investig Radiol 55:601\u2013616. https:\/\/doi.org\/10.1097\/RLI.0000000000000666","journal-title":"Investig Radiol"},{"key":"4088_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/neuonc\/noy133","volume":"21","author":"JY Kim","year":"2019","unstructured":"Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, Yoo RE, Choi SH, Kim HS (2019) Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol 21:404\u2013414. https:\/\/doi.org\/10.1093\/neuonc\/noy133","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04088-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T04:13:41Z","timestamp":1663215221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04088-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4088"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04088-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742308650.793595187","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BME is on advisory board of Hoffman La-Roche, Siemens, Nativis, Medicenna, MedQIA, Bristol Meyers Squibb, Imaging Endpoints, and Agios. BME is a paid consultant of Nativis, MedQIA, Siemens, Hoffman La-Roche, Imaging Endpoints, Medicenna, and Agios. BME has grant funding by Hoffman La-Roche, Siemens, Agios, and Janssen. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the applicable independent ethics committee and institutional review board at each participating institution. All patients provided written informed consent to participate in the AVAglio trial (NCT00943826) and the clinical trial adhered to the principles of the Declaration of Helsinki and the Guidelines for Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}